Edition:
United Kingdom

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,066.00DKK
14 Aug 2018
Change (% chg)

kr.-19.50 (-1.80%)
Prev Close
kr.1,085.50
Open
kr.1,091.50
Day's High
kr.1,091.50
Day's Low
kr.1,062.00
Volume
130,456
Avg. Vol
225,106
52-wk High
kr.1,474.00
52-wk Low
kr.880.80

Latest Key Developments (Source: Significant Developments)

Genmab Q2 Operating Result at DKK 135 mln
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST HALF OF 2018.IS MAINTAINING ITS 2018 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 21, 2018.REVENUE WAS DKK 1,191 MILLION IN FIRST HALF OF 2018 COMPARED TO DKK 1,024 MILLION IN FIRST HALF OF 2017.OPERATING INCOME WAS DKK 459 MILLION IN FIRST HALF OF 2018 COMPARED TO DKK 582 MILLION IN FIRST HALF OF 2017.Q2 REVENUE DKK 509.7 MILLION (REUTERS POLL DKK 460 MILLION).Q2 OPERATING RESULT DKK 135.0 MILLION (REUTERS POLL DKK 79.1 MILLION).ROYALTY INCOME AMOUNTED TO DKK 709 MILLION IN THE FIRST HALF OF 2018 COMPARED TO DKK 479 MILLION IN THE FIRST HALF OF 2017.MILESTONE INCOME WAS DKK 40 MILLION IN THE FIRST HALF OF 2018 WHICH WAS DRIVEN BY THE JANSSEN AND NOVO NORDISK DUOBODY COLLABORATIONS.  Full Article

Genmab Q2 DARZALEX Net Sales At USD 511 Million
Tuesday, 17 Jul 2018 

July 17 (Reuters) - GENMAB A/S ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR SECOND QUARTER OF 2018.NET SALES OF DARZALEX IN Q2 OF 2018 TOTALED USD 511 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..NET SALES WERE USD 298 MILLION IN U.S. AND USD 213 MILLION IN REST OF WORLD..  Full Article

Genmab Enters Strategic Partnership With Immatics
Thursday, 12 Jul 2018 

July 12 (Reuters) - Genmab A/S ::REG-GENMAB ENTERS STRATEGIC PARTNERSHIP WITH IMMATICS TO DISCOVER AND DEVELOP NEXT GENERATION BISPECIFIC CANCER IMMUNOTHERAPIES.ENTERED INTO A RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH PRIVATELY OWNED IMMATICS BIOTECHNOLOGIES GMBH.IMMATICS TO RECEIVE UPFRONT PAYMENT OF USD 54 MILLION FROM GENMAB.WILL RECEIVE AN EXCLUSIVE LICENSE TO THREE PROPRIETARY TARGETS FROM IMMATICS.NEWS DOES NOT IMPACT GENMAB'S 2018 FINANCIAL GUIDANCE.  Full Article

Genmab Says Will Increase Share Capital By 155,576 Shares
Tuesday, 15 May 2018 

May 15 (Reuters) - Genmab A/S ::CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE.WILL INCREASE ITS SHARE CAPITAL BY 155,576 SHARES AS A CONSEQUENCE OF THE EXERCISE OF EMPLOYEE WARRANTS.INCREASE CORRESPONDS TO APPROX. 0.25 % OF THE COMPANY'S SHARE CAPITAL.TOTAL NOMINAL VALUE OF SHARE CAPITAL AFTER INCREASE IS DKK 61,436,818 CORRESPONDING TO 61,436,818 VOTES.  Full Article

Genmab Q1 Operating Result DKK 324 Million, Below Expectations
Tuesday, 8 May 2018 

May 8 (Reuters) - Genmab A/S ::REG-INTERIM REPORT FIRST QUARTER 2018.REVENUE WAS DKK 681 MILLION IN Q1 OF 2018 COMPARED TO DKK 251 MILLION IN Q1 OF 2017.OPERATING INCOME WAS DKK 324 MILLION IN Q1 OF 2018 COMPARED TO DKK 46 MILLION IN Q1 OF 2017.IS MAINTAINING ITS 2018 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 21, 2018..Q1 REVENUE DKK 681 MILLION (REUTERS POLL DKK 684 MILLION).Q1 OPERATING RESULT DKK 324 MILLION (REUTERS POLL DKK 358 MILLION).OPERATING EXPENSES WERE DKK 357 MILLION IN Q1 OF 2018 COMPARED TO DKK 205 MILLION IN Q1 OF 2017.Q1 NET PROFIT DKK 198.6 MILLION (REUTERS POLL DKK 282 MILLION).  Full Article

Genmab gets U.S. FDA approval of Darzalex in newly diagnosed multiple Myeloma
Monday, 7 May 2018 

May 7 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES U.S. FDA APPROVAL OF DARZALEX (DARATUMUMAB) IN NEWLY DIAGNOSED MULTIPLE MYELOMA.GENMAB - FDA SUBSEQUENTLY GRANTED PRIORITY REVIEW TO SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION, WITH PRESCRIPTION DRUG USER FEE ACT TARGET DATE OF MAY 21.  Full Article

Genmab: Q1 Net Sales Of Darzalex At $432 Mln
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Genmab A/S ::REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018.NET SALES OF DARZALEX IN Q1 OF 2018 TOTALED USD 432 MILLION.WILL RECEIVE ROYALTIES ON WORLDWIDE SALES FROM JANSSEN BIOTECH, INC.  Full Article

Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - GENMAB ::ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB).‍WORLDWIDE NET SALES OF DARZALEX (DARATUMUMAB) AS REPORTED BY JOHNSON & JOHNSON WERE USD 1,242 MILLION IN 2017​.‍NET SALES WERE USD 884 MILLION IN U.S. AND NET SALES IN REST OF WORLD WERE USD 358 MILLION​.  Full Article

U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Genmab A/S ::U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA.GENMAB - FDA HAS ASSIGNED PDUFA TARGET DATE OF MAY 21, 2018 TO TAKE A DECISION ON DARATUMUMAB IN THE INDICATION.  Full Article

Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Genmab A/S ::GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO.MAJOR SHAREHOLDER ANNOUNCEMENT.  Full Article

Photo

Italian stocks plummet after roller-coaster day as vote looms

MILAN Italian stocks slumped on Monday at the end of a roller-coaster session as investors fretted that new elections could see anti-establishment parties win more support.